Home > Resources > Whitepapers > Split protein biosensor assays in molecular pharmacological studies

Split protein biosensor assays in molecular pharmacological studies

Cellular signalling is commonly mediated through dynamic protein– protein interactions (PPIs). When pivotal PPIs are deregulated, cellular signalling can be altered; itis therefore attractive to monitor regulated PPIs to understand their role in health and disease. Genetically encoded biosensors that rely on protein fragment complementation have made it feasible to monitor PPIs in living cells precisely and robustly.

Spotlight

Bellicum Pharmaceuticals, Inc.

Bellicum Pharmaceuticals, located near the Houston Medical Center, is a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies for various forms of cancer, including both hematological and solid tumors, as well as orphan inherited blood disorders. We are developing next-generation product candidates in some of the most important areas of cellular immunotherapy, including hematopoietic stem cell transplantation (HSCT) and CAR T cell therapy.

OTHER WHITEPAPERS

Patients Diagnosed with Post-COVID Conditions

whitePaper | May 18, 2022

Post-COVID conditions, also known by such terms as long COVID and post-acute sequelae of COVID-19, have become an issue of growing national concern.

The Ultimate Guide to Digitizing Pharma Manufacturing

whitePaper | September 15, 2022

The sheer size of the pharmaceutical industry makes it important for all stakeholders to stay up to date with pharmaceutical industry trends.

The Impact of Rising Generic Drug Prices on the U.S. Drug Supply Chain

whitePaper | April 16, 2020

Over the past two years, the pharmacy industry has seen unprecedented increases in the prices of generic drugs, causing unexpected cost increases for payers and consumers, and spurring an investigation by the United States Congress. High generic drug prices have had an adverse effect on almost everyone in the pharmaceutical supply chain. Consumers face higher co-pays and prices and health plans are dealing with higher drug spend. Physicians are finding the need to prescribe alternative drug therapies while dealing with angry patients.

Defragmenting Data for the Future of Pharma R&D

whitePaper | November 7, 2019

This in-depth paper will show you how to become data agile – tackling both technological issues and solutions, and the cultural and strategic framework needed around this to ensure success.

Best Practices for RIM Business Process Automation

whitePaper | December 29, 2022

Regulatory teams at life science companies are finding that effective regulatory information management (RIM) has become critical to their operations.

High Pressure Homogenizer for Nano-formulation

whitePaper | December 16, 2022

NanoGenizer, a lab-scale microfluidic high pressure homogenizer, utilizes interaction high-pressure microfluidic jet technology, and it is equipped with highly modular power and processing units.